-0.03 (-3.846%)
ASX:Live
Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Neutral
Valuation
Value
Consensus
Momentum
Price
Very Weak
Earnings
Very Strong
Growth
Earnings
Very Strong
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Website
N/A
Telephone
61.8.9329.3396
Address
Unit 4, 117 Broadway Nedlands, Western Australia (WA) 6009
Description
Argenica Therapeutics Ltd. provides neuroprotective treatment. It specializes in development and commercialization of a novel therapeutic known as ARG-007. It offers drug ARG-007 in multiple models of stroke and other central nervous system (CNS) injury models, specifically: stroke including non-human primates; traumatic brain injury; and perinatal hypoxia ischaemia. The company was founded on 20 November 2019 and is headquartered in Nedlands, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.6 - 0.99
Trade Value (12mth)
AU$31,036.00
1 week
7.59%
1 month
18.18%
YTD
22.83%
1 year
26.83%
All time high
1.02
EPS 3 yr Growth
274.50%
EBITDA Margin
N/A
Operating Cashflow
-$5m
Free Cash Flow Return
-46.80%
ROIC
-50.70%
Interest Coverage
N/A
Quick Ratio
6.70
Shares on Issue (Fully Dilluted)
128m
HALO Sector
Healthcare
Next Company Report Date
20-Aug-25
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
| Date | Announcements |
|---|---|
|
30 April 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
11 April 25 |
Last Patient Dosed in Phase 2 Stroke Trial
×
Last Patient Dosed in Phase 2 Stroke Trial |
|
01 April 25 |
Notification of cessation of securities - AGN
×
Notification of cessation of securities - AGN |
|
21 March 25 |
Change of Share Registry Details
×
Change of Share Registry Details |
|
12 March 25 |
Investor Presentation
×
Investor Presentation |
|
03 March 25 |
Non-Executive Director Resignation
×
Non-Executive Director Resignation |
|
03 March 25 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
|
11 February 25 |
Half Yearly Report and Accounts
×
Half Yearly Report and Accounts |
|
04 February 25 |
ARG-007 Shows Significant Neuroprotection in Main TBI Study
×
ARG-007 Shows Significant Neuroprotection in Main TBI Study |
|
04 February 25 |
Updated - Main TBI Injury Study Annoucement
×
Updated - Main TBI Injury Study Annoucement |
|
30 January 25 |
Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
×
Positive DSMB Safety Outcome & Phase 2 Trial Progress Update |
|
30 January 25 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
10 December 24 |
Phase 2 Stroke Clinical Trial Update
×
Phase 2 Stroke Clinical Trial Update |
|
02 December 24 |
Non-Executive Director Appointment
×
Non-Executive Director Appointment |
|
02 December 24 |
Initial Director's Interest Notice
×
Initial Director's Interest Notice |
|
21 November 24 |
$2.76m R&D Tax Incentive Cash Rebate Received for FY24
×
$2.76m R&D Tax Incentive Cash Rebate Received for FY24 |
|
13 November 24 |
Results of Annual General Meeting
×
Results of Annual General Meeting |
|
13 November 24 |
AGM Chair's Address & MD Presentation
×
AGM Chair's Address & MD Presentation |
|
13 November 24 |
Final Director's Interest Notice
×
Final Director's Interest Notice |
|
01 November 24 |
Positive DSMB Safety Outcome & Phase 2 Trial Progress Update
×
Positive DSMB Safety Outcome & Phase 2 Trial Progress Update |
|
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report
×
Quarterly Activities/Appendix 4C Cash Flow Report |
|
31 October 24 |
Quarterly Activities/Appendix 4C Cash Flow Report - updated
×
Quarterly Activities/Appendix 4C Cash Flow Report - updated |
|
30 October 24 |
FDA Grants ODD & RPDD for Second Drug in Treatment of HIE
×
FDA Grants ODD & RPDD for Second Drug in Treatment of HIE |
|
29 October 24 |
Investor Presentation
×
Investor Presentation |
|
24 October 24 |
Non-Executive Director Retirement
×
Non-Executive Director Retirement |
Load More
Load Less
Ex Dividend Date (est.)
DIV Yield
Franking Level
DPSg
Quality Yield
Falling Divs over next 2
Consensus Score
Recommendation
EPS 1 month Change
Quality Yield
Falling Divs over next 2
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
.svg)
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.
